Clinical TrialMay 12, 2026, 04:38 PM
Inhibikase Initiates Phase 3 IMPROVE-PAH Study; Q1 Net Loss $16.4M
AI Summary
Inhibikase Therapeutics announced its first quarter 2026 financial results and significant corporate updates. The company initiated its registrational Phase 3 IMPROVE-PAH study for IKT-001 in Pulmonary Arterial Hypertension (PAH) and enrolled the first patient. Inhibikase also secured European Medicines Agency approval for the Phase 3 study in 12 EU countries, contributing to a total of 16 global country approvals, and submitted an Orphan Drug Designation application to the US FDA for IKT-001. For Q1 2026, the company reported a net loss of $16.4 million, or $0.10 per share, with $170.4 million in cash, cash equivalents, and marketable securities.
Key Highlights
- Initiated registrational Phase 3 IMPROVE-PAH study for IKT-001 in PAH, enrolling first patient.
- Received EMA approval for Phase 3 study in 12 EU countries, bringing total global approvals to 16.
- Submitted Orphan Drug Designation application to US FDA for IKT-001 for PAH.
- Cash, cash equivalents, and marketable securities totaled $170.4 million as of March 31, 2026.
- Reported Q1 2026 net loss of $16.4 million, or $0.10 per share.
- Q1 2026 R&D expenses were $10.8 million, up from $10.5 million in Q1 2025.
- Q1 2026 SG&A expenses were $7.4 million, up from $5.2 million in Q1 2025.
- IKT-001 pre-clinical and Phase 1 data to be presented at ATS International Conference.